Nuo Therapeutics, Inc. (OTCPK: AURX)
Health Care · Biotechnology · US
$1.03
+33.77% today · -34.2% 1Y
Nuo Therapeutics, Inc. (OTCPK: AURX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $49.86M and employs 10 people.
Over the last twelve months the share price has lost 34.2%, trading between 0.77 and 3.23.
Tweenvest scores Nuo Therapeutics, Inc. across four factors: quality 13/100, value 58/100. Its strongest factor is value.
AURX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $49.86M
- Revenue (TTM)
- $5.20M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- -779.39
- 52-week high
- $3.23
- 52-week low
- $0.77
- Avg volume (3M)
- —
- Shares outstanding
- 48.41M
- Employees
- 10
- Next earnings
- —
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
- ISIN
- US67059V2097
- Founded
- 1998
- Listed since
- Oct 24, 2017
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.